GlassScriptPhysician profile
Mohammad Asif Khan
NPI 1669525333
$11,426.19
in general payments reported to CMS, 2019-2025
36 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,760 · 2020: $308 · 2021: $31.72 · 2022: $287 · 2023: $500 · 2024: $199 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.81 |
| Education | $209.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $5,490.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $3,312.68 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $327.24 | 2019-2025 | Imbruvica, Rybrevant |
| Pfizer INC. | $265.65 | 2019-2024 | |
| Lilly USA, LLC | $258.56 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $159.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.03 | 2019-2023 | |
| Glaxosmithkline, LLC. | $124.38 | 2025 | Jemperli |
| Regeneron Healthcare Solutions, INC. | $122.15 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $120.02 | 2019-2022 | |
| Genentech USA, INC. | $113.60 | 2019-2023 | Venclexta, Tecentriq |
| Amgen INC. | $111.80 | 2019-2025 | Kyprolis, Lumakras, Blincyto |
| Merck Sharp & Dohme LLC | $109.33 | 2019-2023 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $108.76 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $84.93 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $78.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $67.99 | 2022 | |
| Exelixis INC. | $55.28 | 2019 | |
| Seagen INC. | $35.57 | 2020-2022 | |
| Karyopharm Therapeutics INC. | $34.63 | 2020 | |
| Celgene Corporation | $31.76 | 2019-2020 | |
| Gilead Sciences, INC. | $26.09 | 2021-2023 | Trodelvy |
| Grifols USA, LLC | $23.82 | 2022 | |
| Amneal Pharmaceuticals LLC | $22.33 | 2023 | Avastin |
| Tolmar, INC. | $21.39 | 2023 | |
| Servier Pharmaceuticals LLC | $20.33 | 2023 | |
| Beigene USA, INC. | $19.80 | 2021 | |
| Emmaus Medical, INC. | $18.05 | 2019 | |
| Astellas Pharma US INC | $17.51 | 2020 | |
| Palette Life Sciences, INC. | $16.76 | 2022 | |
| Dova Pharmaceuticals | $14.60 | 2019 | |
| Agios Pharmaceuticals, INC. | $14.40 | 2019 | |
| Sumitomo Pharma America, INC. | $13.45 | 2023 | Orgovyx |
| Aurobindo Pharma USA, INC. | $13.45 | 2019 | |
| Verastem, INC. | $12.29 | 2019 | |
| Myovant Sciences INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Asif Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.